Haitz Karyn, Khosravi Hasan, Lin Jennifer Y, Menge Tyler, Nambudiri Vinod E
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, University of Miami Miller School of Medicine, Miami, Florida.
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
J Am Acad Dermatol. 2020 Jul;83(1):189-196. doi: 10.1016/j.jaad.2020.01.039. Epub 2020 Jan 28.
Talimogene laherparepvec (T-VEC) is an oncolytic virus based on herpes simplex virus type 1 approved for intralesional treatment of advanced melanoma. In this article, we review the clinical literature on T-VEC for advanced melanoma and provide a practical approach to using T-VEC in the dermatologic surgery and oncology clinic. PubMed was used to conduct a systematic literature review of articles describing the structure, basic science, and clinical and therapeutic properties of T-VEC. The national clinical trials database was also searched for T-VEC clinical trials. Phase I to III clinical trials and early real-world experience have shown the efficacy of T-VEC in advanced melanoma as single or combination therapy with tolerable adverse effects. We conclude that with a standardized clinical approach and training, dermatologists can pave the way in using T-VEC and future oncolytic virus therapies in appropriate clinical scenarios.
talimogene laherparepvec（T-VEC）是一种基于1型单纯疱疹病毒的溶瘤病毒，已被批准用于晚期黑色素瘤的瘤内治疗。在本文中，我们回顾了关于T-VEC治疗晚期黑色素瘤的临床文献，并提供了在皮肤科手术和肿瘤诊所使用T-VEC的实用方法。使用PubMed对描述T-VEC的结构、基础科学以及临床和治疗特性的文章进行系统的文献综述。还在国家临床试验数据库中搜索了T-VEC的临床试验。I至III期临床试验和早期真实世界经验表明，T-VEC作为单一疗法或联合疗法治疗晚期黑色素瘤有效，且不良反应可耐受。我们得出结论，通过标准化的临床方法和培训，皮肤科医生可以为在适当的临床场景中使用T-VEC及未来的溶瘤病毒疗法铺平道路。
